Bone morphogenetic proteins 1 to 7 in human breast cancer, expression pattern and clinical/prognostic relevance

Journal of Experimental Therapeutics and Oncology

Volumn 7, Issue 4, 2008, Pages 327-338

  Davies, Simon R ^a   Watkins, Gareth ^a   Douglas Jones, Anthony ^a   Mansel, Robert E ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

BMP; Bone morphogenetic proteins; Breast cancer

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; CYTOKERATIN 19; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; OSTEOGENIC PROTEIN 1; OSTEOGENIN; PROCOLLAGEN C PROTEINASE;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; BONE MORPHOGENETIC PROTEINS; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; DNA PRIMERS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; LYMPHATIC METASTASIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 58649120032     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. American Cancer Society: Cancer Facts & Figures 2006. Atlanta, GA 2006.
2. Breast In AJCC Cancer Staging Manual fifth Edition (Edited by: Fleming I, Cooper J, Henson D, Hutter R, Kennedy B, Murphy G, O'Sullivan B, Sobin L, Yarbro J). Philadelphia: Lippincott-Raven 1997, 171-178.
3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12: 6243s-6249s.
4. Clement JH, Raida M, Sanger J, Bicknell R, Liu J, Naumann A, Geyer A, Waldau A, Hortschansky P, Schmidit A, Hoffken K, Wolft S, Harris AL. Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncology 2005;27:401-7.
5. Reddi AH. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Nat Biotechnol 1998;16:247-252.
6. Martinovic S, Borovecki F, Vukicevic A. Biology of the BMPs. In: Bone morphogenetic proteins: from laboratory to clinical practice (Vukicevic S, Sampath TK, ed), Birkhauser Verlag, Basel-Boston-Berlin, 2002, 87-119.
7. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation: molecular clones and activities, Science 1988;242:1528-1534.
8. Wozney JM, Rosen V, Byrne M, Celeste AJ, Moutsatsos I, Wang EA. Growth factors influencing bone development. J Cell Sci Suppl 1990;13:149-56.
9. Ozkaynak E, Rueger DC, Drier EA, Corbet C, Ridge RJ, Sampath TK, Oppermann H. OP-1 cDNA encodes an oncogenetic protein in the TGF-beta family. Embo J 2000;9:2085-93.
10. Butler SJ, Dodd J. A role for BMP heterodimers in roof plate-mediated repulsion of commissural axons. Neuron 2003;38:389-401.
11. Shi Y, Massague J. Mechanisms of TGF-beta signalling from cell membrane to the nucleus. Cell 2003;113:685-700.
12. Nohe A, Keating E, Knaus P, Petersen NO. Signalling transduction of bone morphogenetic protein receptors. Cell Signal 2004;16:291-9.
13. Von Bubnoff A, Cho KW. Intracellular cell signalling regulation in vertebrates: Pathway or network? Dev Biol 2001;239: 1-14.
14. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sabald W, Henis YI, Knaus P. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002;277:5330-5338.
15. Re'em-Kalma Y, Lamb T, Frank D. Competition between noggin and bone morphogenetic protein 4 activities may regulate dorsalization during Xenopus development. Proc Natl Acad Sci (USA) 1995;92:12141-5.
16. Gazzerro E, Gangji V, Canalis E. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Inverst 1998;102:2106-14.
17. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA jr, Wrana JL, Falb D. The MAD-related protein Smad 7 associated with the TGFbeta receptor and functions as an antagonist of TGFbeta signalling. Cell 1997;89:1165-73.
18. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K. Smad 6 inhibits signalling by the TGF-beta superfamily. Nature 1997;389:622-6.
19. Luo K, Stroshein SL, Wang W, Chen D, Martens E, Zhou S, Zhou Q. The ski oncoprotein interacts with the Smad proteins to repress TGFbeta signalling. Genes Dev 1999;13:2196-206.
20. Wang W, Mariani FV, Harland RM, Luo K. Ski represses bone morphogenetic protein signalling in Xenopus and mammalian cells. Proc Natl Acad Sci (USA) 2000;97:14394-9.
21. Xu W, Angelis K, Danielpour D, Haddad MM, Bischof O, Campisi J, Stavnezer E, Madrano EE. Ski acts as a co-repressor with Smad 2 and Smad 3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci (USA) 2000;97:5924-9.
22. Yoshiada Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N, Hosode E, Imamura T, Kuno J, Yamashita T, Miyazono K, Noda M, Noda T, Yamamoto T. Negative regulation of BMP/Smad signalling by Tob in oesteoblasts. Cell 2000;103:1085-97.
23. Yoshiada Y, von Bubnoff A, Ikematsu N, Blitz, IL, Tsuzuku JK, Yoshida EH, Umemori H, Miyazono K, Yamamoto T, Cho KW. Tob proteins enhance inhibitory Smad-receptor interactions to repress BMP signalling. Mech Dev 2003;120:629-37.
24. Arora K, Warrior R. A new Smurf in the village. Dev Cell 2001;1:441-2s.
25. Lee S, Solow-Cordero DE, Kessler E, Takahara K, Greenspan DS. Transforming Growth Factor-β Regulation of Bone Morphogenetic Protein-I/Procollagen C-proteinase and Related Proteins in Fibrogenic Cells and Keratinocytes. J. Biol Chem 1997;272:19059-19066.
26. Arnold SF, Tims E, Mcgrath BE. Identification of none morphogenetic proteina and their receptors in human breast caner cell lines: importance of BMP 2. Cytokine, 1999;11:1031-7.
27. Clement JH, Marr N, Meissner A, Schwalbe M, Sebald W, Kliche KO, Hoffken K, Wolfl S. Bone morphogenic protein 2 (BMP-2) induces sequential changes of Id gene expression in the breast cancer cell line MCF-7. J Cancer Res Clin Oncol. 2000;126:271-9.
28. Kraunz KS, Nelson HH, Lie M, Wiencke JK, Kelsey KT. Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer. Br J Cancer. 2005;93:949-52.
29. Alarmo EL, Kuukasjarvi T, Karhu R, Kallioniemi A. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP 4 and BMP 7. Breast Cancer Res Treat. 2007;103:239-46.
30. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, Gladstone H, Chang HY, Morganroth GS, Oro AE, Brown PO. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A. 2006;103:14842-7.
31. Bently H, Hamdy FC, Hart KA, Seid JM, Williams JL, Johnstone D, Russell RG. Expression of bone morphogenic proteins in human prostate adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992;66:1159-63.
32. Barnes JL, Zhang Y, Samad TA, Xla Y, Tang J, Campagna JA, Scheneyer AL, Woolf CJ, Lin HY. Repulsive guidance molecule (RGMa). A DRAGON homologue, is a bone morphogenic protein co-receptor. J Biol Chem 2005;280:29820-27.
33. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN. Immunolocalization and messenger RNA expresssion of bone morphogenetic protein 6 in human benign and malignant prostatic tissue. Cancer Res 1997;57:4427-31.
34. Schwalbe M, Sanger J, Eggers R, Naumann A, Schmidt A, Hoffken K, Clement JH. Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. Int J Oncol. 2003;23: 89-95.
35. Sulzbacher I, Birner P, Trieb K, Pichlbauer E, Lang S. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J. Clin Pathol. 2002;55:381-5.
36. Hanavadi S, Martin TA, Mansel RE, Jiang WG. The role of Growth Differentiation Factor-9a (GDF-9a) and its analogue, GDF9b (BMP-15, in human breast cancer. Ann Surg Oncol 2007;14:2159-66.
37. Jiang WG, Watkins G, Martin TA, Sampson J, Lee-Jones L, Kefah Mokbel, Mansel RE. The expression of TSC genes in human breast cancer. Eur J Cancer, 2005;41:1628-1636.
38. Davies S, Watkins G, Mansel RE, Jiang WG. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer.. Ann Surg Oncol, 2007; 14:1909-1918in press.
39. Nazarenko IA, Bhatnagar SK, Hohman RJ. A closed tube format for amplification and detection of DNA based on energy transfer. Nucleic Acids Res. 1997;25:2516-2521.
40. Jiang WG, Douglas-Jones A, Mansel RE. Level of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids. 2003a;69: 275-281.
41. Jiang WG, Douglas-Jones A, Mansel RE. Expression of peroxisome- proliferator activated receptor-gamma (PPARγ) and the PPARgamma co-activator. PGC-1 in human breast cancer correlates with clinical outcomes. Int J Cancer. 2003b;106:752-757.
42. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K, Mansel RE. Prognostic value of Rho GTPases and Rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res. 2003c;9:6432-6440.
43. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res. 2004;10:202-211.
44. King J, Ofori-Acquash A, Stevens T, Al-Mehdi A, Fodstad O, Jiang W. Activated leukocyte adhesion molecule in breast cancer: prognostic indicator. Breast Can. Res. 2004;6:478-487.
45. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992. 22:207-219.
46. Raida M, Heymann AC, Gunther C, Niederwieser D. Role of bone morphogenetic protein 2 in the crosstalk between endothelial progenitor cells and mesenchymal stem cells. Int J Mol Med. 2006 Oct;18:735-9.
47. Sakou T. Bone Morphogenetic Proteins: From basic studies to clinical approaches Bone 1998;6:591-603.
48. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation: molecular clones and activities. Science 1998;242:128-34.
49. Clancy BM, Johnson JD, Lambert AJ, Rezankhah S, Wong A, R emini C, Feldman JL, Lappanen S, Pittman DD. Bone 2003;33:46-63.
50. Kusafuka K, Yamaguchi A, Kayano T, Fujiwara M, Takemura T. Expression of bone morphogenetic proteins in salivary pleomorphic adenomas. Virchows Arch. 1998;432:247-53.
51. Sulzbacher I, Birner P, Trieb K, Pichlbauer E, Lang S. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol. 2002;55:381-5.